Consumo de medicamentos inhibidores de la resorción ósea en adultos mayores en un Establecimiento Farmacéutico de Trujillo, febrero – julio 2018

The purpose of this report was to determine the characteristics and trends of consumption of bone resorption inhibitor drugs in older adults in a clinical protocol of the district of Trujillo, from February to July 2018, based on the information in the report of the inhibitors dispensed in said establishment were processed into double entry tables format, which were converted to DDD, and then a linear regression analysis using the Pearson R2 to establish the trend with a 95% confidence level (P < 0, 05). According to the results obtained in the monthly consumption of bone resorption inhibitor drugs, they did not show a significant tendency, taking alendronic acid R2 = 0.6454 (p = 0.054), ibandronic acid R2 = 0.0717 (p = 0.608), acid zoledronic R2 = 0.0857 (p = 0.573) and denosumab R2 = 0.5681 (p = 0.084). The trend varies in the No DDD chart per 1000 inhabitants / day, for alendronic acid R2 = 0.4653 (p = 0.134), ibandronic acid R2 = 0.002 (p = 0.934), zoledronic acid R2 = 0.1976 (p = 0.388) and denosumab R2 = 0.4394 (p = 0.152). Therefore, it is concluded that the trend is downward in all inhibitors of bone resorption in older adults, in 2018. According to pharmaceutical specialty, the No DDD has the highest tendency with a rotation of 25.86 DDD per 1000 inhabitants / day. February month